At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
852Adrug
Likely dose
852A 0.6 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers
Masonic Cancer Center, University of Minnesota·interventional·Posted Apr 27, 2006·Updated Aug 26, 2019
In Brief
A Phase 2 clinical trial evaluating 852A for Breast Cancer and 3 related conditions. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat metastatic breast, ovarian, endometrial or cervical cancer not responding to standard treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedApr 2006
Primary CompletionDec 2007
Study CompletionDec 2008
TodayJul 2026
First PostedApr 27, 2006
Enrollment StartApr 1, 2006
Primary CompletionDec 1, 2007
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 20.2 years ago
Interventions
852Adrug
0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.